Legal & General Group
TXG icon

Legal & General Group’s 10x Genomics TXG Stock Holding History

Legal & General Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.76M Buy
97,998
+6,065
+7% +$159K ﹤0.01% 1710
2026
Q1 		$1.95M Sell
91,933
-9,963
-10% -$199K ﹤0.01% 1920
2025
Q4 		$1.66M Sell
101,896
-14,482
-12% -$219K ﹤0.01% 2047
2025
Q3 		$1.36M Buy
116,378
+5,514
+5% +$71.9K ﹤0.01% 2146
2025
Q2 		$1.28M Buy
110,864
+5,985
+6% +$54.6K ﹤0.01% 2160
2025
Q1 		$916K Buy
104,879
+3,034
+3% +$38.2K ﹤0.01% 2216
2024
Q4 		$1.46M Sell
101,845
-113
-0.1% -$1.78K ﹤0.01% 2111
2024
Q3 		$2.3M Buy
101,958
+12,642
+14% +$261K ﹤0.01% 1908
2024
Q2 		$1.74M Buy
89,316
+4,359
+5% +$114K ﹤0.01% 1999
2024
Q1 		$3.19M Buy
84,957
+602
+0.7% +$26.4K ﹤0.01% 1728
2023
Q4 		$4.72M Buy
84,355
+501
+0.6% +$21.8K ﹤0.01% 1530
2023
Q3 		$3.46M Sell
83,854
-1,884
-2% -$98K ﹤0.01% 1638
2023
Q2 		$4.79M Buy
85,738
+660
+0.8% +$35.7K ﹤0.01% 1485
2023
Q1 		$4.75M Buy
85,078
+6,680
+9% +$312K ﹤0.01% 1441
2022
Q4 		$2.86M Sell
78,398
-7,331
-9% -$240K ﹤0.01% 1704
2022
Q3 		$2.44M Sell
85,729
-23,524
-22% -$896K ﹤0.01% 1761
2022
Q2 		$4.94M Sell
109,253
-210,088
-66% -$10.9M ﹤0.01% 1416
2022
Q1 		$24.3M Buy
319,341
+66,228
+26% +$5.79M 0.01% 831
2021
Q4 		$37.7M Sell
253,113
-19,761
-7% -$3.03M 0.01% 741
2021
Q3 		$39.7M Buy
272,874
+10,384
+4% +$1.78M 0.01% 720
2021
Q2 		$51.4M Buy
262,490
+78,846
+43% +$14.3M 0.02% 683
2021
Q1 		$33.2M Buy
183,644
+11,636
+7% +$2.01M 0.01% 749
2020
Q4 		$24.4M Buy
172,008
+140,135
+440% +$20.3M 0.01% 789
2020
Q3 		$3.97M Buy
31,873
+10,107
+46% +$1.06M ﹤0.01% 1455
2020
Q2 		$1.94M Buy
+21,766
New +$1.7M ﹤0.01% 1744
2020
Q1 		– Sell
-7,000
Closed -$532K – 3358
2019
Q4 		$532K Buy
7,000
+1,500
+27% +$90.2K ﹤0.01% 2208
2019
Q3 		$278K Buy
+5,500
New +$304K ﹤0.01% 2285

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legal & General Group's TXG Position: Q2 2026 in Review

Legal & General Group increased its 10x Genomics (TXG) stake by 6.6% in Q2 2026, buying an estimated $159K and bringing the position to 97,998 shares worth $3.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1710.

Legal & General Group first reported a position in TXG in Q3 2019 and has held it in 27 quarters since. The position peaked at $51.4M in Q2 2021. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Legal & General Group held 97,998 shares of 10x Genomics worth $3.76M as of Q2 2026.
  • Legal & General Group bought 6,065 10x Genomics shares in Q2 2026, an estimated $159K.
  • 10x Genomics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1710 holding.
  • Legal & General Group first reported a position in 10x Genomics in Q3 2019 and has held it in 27 quarters since.
  • Legal & General Group's 10x Genomics position peaked at $51.4M in Q2 2021.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.